Abstract: Cancer heterogeneity is associated with drug resistance, risk of disease recurrence and metastasis. Pathology allows for the assessment of heterogeneity in the tumor. However, this assessment is limited to an overall assessment of the tumor microenvironment (TME), through measurement…
Abstract: With the rapidly changing landscape of early-stage breast cancer, there is a significant need for upfront biomarkers to enable physicians to “right-size” therapy for patients. It is well known that tumor heterogeneity drives the variability of response to neoadjuvant…
Abstract: Heterogeneity is a hallmark of cancer and perhaps one of the most important features associated with resistance to therapies and likelihood of recurrence and/or metastasis. Genomic instability contributes to genetic diversity, which leads to high levels of intratumoural heterogeneity.…
Abstract: Breast cancer (BC) progression during NAT is associated with development of distant metastases, positive LN status, and decreased OS/RFS. These can occur in the context of clinical trials and therapy de-escalation, where the focus is on delivering effective NAT…
Abstract: TNBC is the most aggressive of breast cancer subtypes and lacks targeted therapies. Thus, tumor aggressiveness is an important factor to determine escalation of care for TNBC patients. Currently, aggressiveness is evaluated based on tumor spread and markers of…
Abstract: Background: Metabolic disfunction is one of the hallmarks of cancer, and metabolism-based therapies are a key class of chemotherapeutics. Despite this, there has previously been no systematic way to identify metabolism-based targets for therapeutic intervention. This is especially concerning…
Abstract: Background: One of the hallmarks of cancer is metabolic dysregulation that has been therapeutically targeted with metabolism-based therapies, an important class of chemotherapeutics. However, there has previously been no systematic way to identify key targets for metabolism-based therapeutic interventions.…
Abstract: Background: Tumor cells are able to reprogram their metabolism in order to sustain continuous growth and proliferation. Although, this has led to the development of metabolism-based therapies, until now there are no systematic ways to identify key metabolic targets…
Abstract: Neoadjuvant Therapy (NAT) for breast cancer results in higher rates of breast conservation surgery. Importantly, there is data supporting the use of multiple NAT regimens, with little guidance as to which one would be most effective for a given…
Abstract: Tumor heterogeneity, understood as the intrinsic (e.g., mutations, dysregulation, metabolic reprogramming) and extrinsic (e.g., nutrient/drug perfusion, interactions with surrounding tissues and the tumor microenvironment (TME)) to the cells that constitute the tumor, drives the variability of response to neoadjuvant…
SOLUTIONS
RESOURCES
©SimBioSys